2021 Revenues ($USD) : $3,094,238,000
2021 R&D spend : $505,748,000
2021 Number of Employees : 3,200
Fiscal Year End : 12/31/2021
Leader : CEO Bruce Cozadd

Jazz Pharmaceuticals specializes in developing therapies in neurosciences, hematology and oncology. Its best-selling drug is Xyrem for treating cataplexy and excessive daytime sleepiness in adult and pediatric patients with narcolepsy. Other bestsellers include Epidiolex/Epidyolex (cannabidiol) to treat seizures associated with two forms of epilepsy, and Zepzelca, a treatment for metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. In May 2021, the Dublin, Ireland–based company completed its $7.2 billion acquisition of GW Pharmaceuticals. —BB